Because of the availability of modern improved XPO1 inhibitors, their logical applications in leukemias with specific mutations, myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), non-Hodgkin’s lymphoma (NHL), and multiple myeloma (MM) may be more rational and involve combinations with old and new drugs. The gene discussed is XPO1; the disease is Miyoshi myopathy.